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ABSTRACT 
Successful Immunotherapy to Malignant Cells with 
Monoclonal Antibody to Suppressor T Cells 
Andres Felipe Rodriguez 
1988 
Potent suppression of the growth of the progressive 31-52 
methylcholanthrene-induced fibrosarcoma was observed in 
syngeneic C3H/HeN mice following treatment with a rat 
monoclonal antibody (mAb) raised against suppressor-effector 
T cells. Treatment of tumor-bearing animals with as little 
as lOug of purified mAb 14-12 three times a week for four 
weeks lead to a significant decrease in tumor growth. The 
protective effects were not witnessed when mAb Y-3Ag, a rat 
antibody of identical isotype as the 14-12 hybridoma but of 
unknown antigen specificity, was used. Animals which resist 
a challenge of 31-52 tumor by treatment with mAb 14-12 show 
no macroscopic evidence of tumor relapse greater than 4 
months after termination of treatment. Treatment with mAb 
14-12 was shown to interfere with the activity of Ts cells 
and not other effector T cell populations. It is concluded 
that mAb 14-12 enhances tumor resistance in C3H/HeN mice by 
eliminating tumor-associated suppressor T cells, and this 
enhancement leads to increased tumor specific resistance. 
Another phenomenon, that of augmentation of tumor growth, 
was also noted in mice treated with mAB 14-12 if low doses 
were used or when tumor growth was observed to progress 
poorly in control animals. Several possible explanations 
are discussed. 
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INTRODUCTION 
The immune response to malignant cells is very complex. 
Despite the demonstration in tumor-bearing animals of immune 
reactivity to autochthonous tumor antigens (85) and the 
existence of a number of immune mechanisms which react to and 
eliminate tumor cells (3), some tumors continue to grow and 
eventually kill the host. The progressive growth of tumor 
cells in otherwise immunocompetent syngeneic animals has been 
attributed to a number of intricate tumor and host factors 
that lead to a breakdown of a normally competent immune 
response. One well documented method of escaping 
immunosurveillance is the tumor-induced generation of 
suppressor T (Ts) cells (4,5,8,11,12,13,22,29,30,31,53,54, 
61,67,88,89,96,97,99,104,105). Tumor-associated Ts cell 
activity has been shown in a large number of tumor systems 
(reviewed in 67), and it has been postulated that reduction 
or elimination of Ts cells is critical for generating tumor 
rejection mechanisms in vivo (5). 
While a number of agents which reduce or eliminate 
suppressor T cell activity in vivo have been used with 
varying success in the treatment of malignant disorders 
(10,16,29,36,44,89), these agents have other effects on the 
immune system as well. In the best study to date on the 




antiserum (36) or monoclonal antibody (10) was used to 
selectively eliminate suppressor T cell activity in tumor 
resistance studies with highly significant results. However, 
it has subsequently been shown that the I-J determinant is 
expressed on antigen-presenting cells (68), contrasuppressor 
T cells (Tcs; 115), T augmenting cells (76) and even subsets 
of helper T cells (Th; 57,101). Therefore, the selective 
role of suppressor T cells in enhancing tumor growth could 
not be determined in these studies. 
The purpose of the current research was to study how the 
activity of Ts cells can be selectively manipulated to 
increase the immune response to malignantly transformed 
cells. It is hypothesized that treatment with a monoclonal 
antibody (mAb) specific for Ts cells and their soluble 
factors (TsF) will result in an enhanced immune response and 
rejection of the tumor. The antibody used in this study, mAb 
14-12, was generated by immunization of rats with purified 
suppressor T cell factor from mice. This antibody has been 
shown to be specific for suppressor effector T cells and to 
block the biological activity of these cells in vitro (19) 
and in vivo (20,21,88). 
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REVIEW OF LITERATURE 
In 1908, the German bacteriologist Paul Ehrlich 
postulated that cancer cells arise frequently, they bear 
antigens on their surface membranes which could be detected 
as foreign by the host, and the immune system may be able to 
reject most of these cells (14). Based on Ehrlich's 
hypotheses, Thomas later formulated the theory of immune 
surveillance (106) which predicts that if cancer cells are 
immunogenic, they should induce an immune response in the 
host. Tumors that do form must then result from an 
immunoresistant cancer or an ineffective immune response. 
It is generally accepted that many tumors may escape 
immunosurveillance by suppression of the immune response. 
What follows is a brief overview of tumor immunology and a 
review of the role of suppressor T (Ts) cells. 
Antigenicity of Tumors and the Nature of Host Immunity 
The fact that tumors possess surface antigens (tumor- 
associated antigen, TAA) against which an immunocompetent 
host can mount an immune response was first shown by Foley 
(27). The initial problem in tumor immunology was not in 




attributing the immune response observed in animals with 
transplanted tumors to the tumor and not to 
histocompatibility differences between the tumor and the 
recipient. By 1957 with the availability of syngeneic 
animals and syngeneic tumor cell lines, the existence of 
specific cell-mediated immunity (CMI) to tumors was well 
established. In a landmark study, Prehn and Main (85) 
completely excised a carcinogen-induced tumor from an 
original host and transplanted varying numbers of tumor 
cells to syngeneic hosts. The smallest number of cells 
required to obtain tumors in all the recipient animals was 
determined. Retransplantation of this number of cells, 
called the LD10a, into the original host usually resulted in 
no tumor growth, while control animals receiving the same 
number of cells developed tumors. They also found that the 
adoptive transfer of lymphocytes from the resistant animals 
to naive recipient animals resulted in specific 
transplantation resistance to the original tumor in 
recipient mice. This was later confirmed when it was shown 
that immunity to syngeneic tumors could be transferred by 
lymphocytes but not with serum from immune donors (21). 
In an elegant study, Algire et al. (1) demonstrated 
that CMI is more significant than humoral immunity in tumor 
rejection. He used diffusion chambers with pores that 
allowed passage of molecules but not cells. Tumor cells 
were placed in these chambers and implanted into immune 
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hosts. Under these conditions the tumor cells survived and 
multiplied even though antibody could be detected bound to 
the tumor surface. When the experiment was repeated with 
diffusion chambers that allowed passage of cells, as well as 
molecules, the tumor cells were rejected and the tumor mass 
was found to be infiltrated by host inflammatory cells. 
Upon further examination, it has been found that while 
tumors of the hematolymphoid system are generally 
susceptible to both humoral and cellular immunity (56,114), 
most tumors are not susceptible to attack by antibody alone 
or by antibody and complement, but rather are only sensitive 
to attack by the elements of CMI--cytotoxic T (Tc) cells, 
killer (K) cells, natural killer (NK) cells and macrophages 
(56,114). It is not known whether all systems function 
against all tumor cells or whether some tumors selectively 
induce one type of cel1-mediated immune response over 
another. 
Tumor Escape Mechanisms 
As stated by North (70), the central question of tumor 
immunology is: Why do immunogenic tumors grow progressively 
in immunocompetent hosts? The fact that tumor cells can 
grow progressively and sometimes metastasize, despite the 
existence of immune responses capable of rejecting them, 
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implies that there exist some mechanism or mechanisms that 
prevent the antitumor response from being effective in vivo. 
and that these mechanisms are more effective at the local 
rather than systemic levels. Several different mechanisms 
of tumor escape have been observed in experimental tumors: 
Tolerance--Circulating tumor antigen or tumor cells 
themselves may induce tolerance (80). This means that the 
immune system is rendered specifically unresponsive to these 
tumor antigens and the tumor can then continue to grow 
unimpeded. Tolerance in many antigen systems has been shown 
to be Ts cel1-mediated (111). 
Immunoselection-- It has been postulated that tumors are 
unicellular in origin and that progression of a tumor occurs 
by sequential selection of variant mutant subpopulations 
which are more adapted to an environment (75). This 
theory, known as the Clonal Selection Theory, is based upon 
the fact that an essential characteristic of all malignant 
cells is genetic instability. The same process that 
resulted in the development of a neoplastic cell (i.e. 
mutation), allows a tumor to adapt to new environments. 
Thus, an ongoing immune response or external antitumor 
therapy may destroy many tumor cells, but allow resistant 
cells to "sneak through" and clonally expand. Many 
different mechanisms can make a tumor cell resistant; for 

7 
example, weak immunogenicity, lack of TAA, different 
metabolic sensitivities, or the ability to induce Ts cell. 
Antigen Modulation--In the presence of an ongoing immune 
response , tumor cells may lose or hide their original 
antigens by endocytosis and express a new set of antigens or 
no antigen (77). 
Immunostimulation--Prehn and co-workers (83,84) have 
proposed that weak immunological responses to either small 
doses of tumor cells or weakly immunogenic tumor antigens 
may result in stimulation rather than inhibition of tumor 
growth. The mechanism is not known but possibilities 
include tumor stimulation by lymphokines (released from 
lymphocytes), or the preferential activation of Ts cells. 
Also, some aspects of the humoral immune response against 
tumor cells may stimulate tumor cell proliferation rather 
than destruction. The stimulation response may be similar 
to the stimulation of thyroid cells by antithyroid 
antibodies in Grave’s disease (43). 
Blocking Mechanisms --A high local concentration of TAA in 
the main tumor mass and free circulating TAA may block 
action of free antitumor antibody and T lymphocytes (56). 
Secondly, noncytotoxic antibodies may bind to TAA and block 
cytotoxic responses or the induction of cytotoxic responses 
(45 ) . 
Immunosuppression--Many tumor bearing patients and animals 
typically exhibit a general suppression of immunity that is 
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dependent on the tumor load (41). The classic example of 
immunosuppressed cancer patients is those with Hodgkin's 
Disease. These patients demonstrate a potent suppression of 
CMI as evidenced by poor DTH responses and increased 
incidence of intracellular parasitic infections such as 
tuberculosis (42). 
The immune suppression evident in tumor-bearing hosts 
could be mediated by a number of mechanisms. Given the key 
regulatory role of suppressor T cells (6), it seems likely 
that these cells are at least partially responsible for the 
progressive growth of immunogenic tumors. Increased 
suppressor cell function has been demonstrated in numerous 
types of human cancer (3): osteogenic sarcoma, bladder 
cell carcinoma, Hodgkin's lymphoma, multiple myeloma, acute 
leukemia, colon carcinoma, head and neck cancer, lung 
cancer, and melanoma. The subject of Ts cells favoring 
tumor growth will be discussed in more detail in the next 
section. 
Ts Cells and Tumor Growth 
Despite extensive evidence for the existence of CMI 
against tumors, the immune system sometimes appears to 
ignore or respond weakly to antigenic stimuli delivered by 
autochthonous tumor cells. Ortiz de Landazuri and Herberman 
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noted that no cell-mediated immune response could be 
detected in tumor bearing hosts after a tumor had progressed 
beyond a certain size (79). However, if host lymphocytes 
were incubated in tissue culture media for 24 hours and then 
replaced in tumor bearing animals (TBA), a specific 
cytotoxic immune response could be detected against the 
tumor. These results suggested the in vivo suppression of 
cell-mediated immune responses to some tumors. 
The concept that Ts cells are responsible for certain 
states of unresponsiveness seen with conventional antigen or 
tumor systems arose from the initial observations of Gershon 
and his colleagues (33,34). The fact that mice bearing a 
variety of established tumors possess or can generate Ts 
cells is well documented (reviewed in 67). However, the 
mere possession or generation of Ts cells does not by itself 
demonstrate that these cells are responsible for the 
progressive growth of immunogenic tumors. Direct evidence 
linking Ts cells with progressive tumor growth can only be 
obtained when it is shown that the generation of tumor- 
induced Ts cells results in both the down regulation of an 
active antitumor immune response and progressive tumor 
growth. 
Toward this end, Fujimoto et al. (29) have shown that 
the immune response to tumors implants in immunized animals 
could be suppressed by the transfer of thymus or spleen 
cells but not with serum from TBA or with thymus or spleen 
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cells from normal animals. In this study the 
methylcholanthrene-induced sarcoma 1509a was used. It was 
found that when normal A/Jax mice received 10* tumor cells 
all mice died within 40 days. However, syngeneic mice that 
had been rendered highly immune to the tumor by multiple 
implantations and resections, rejected the tumor within 14 
days. The rejection of the tumor could be significantly 
inhibited by passive transfer of thymus or spleen cells from 
TBA, but the inhibitory effect was abolished by pretreatment 
of cells with anti-thymocyte serum. Fujimoto's group has 
also shown that the inhibition of tumor rejection was 
dependent on the number of thymus or spleen cells 
transferred. Based on these results, it was hypothesized 
that there exist immunosuppressor cells in TBA which are T 
cells and are capable of inhibiting the antitumor immune 
response. 
These results were later confirmed by Berendt and North 
(4) and Dye and North (11) in two other tumor systems--the 
meth A fibrosarcoma and P815 mastocytoma, respectively. 
Immune mice were obtained by causing the regression of 
established tumors by injection of tumors with bacterial 
endotoxin or Corvnebacterium parvum. It was found that the 
passive transfer of tumor-sensitized T cells from immune 
mice failed to cause regression of established tumors in 
immunocompetent mice, but caused the complete and permanent 
regression of established tumors if the recipient mice had 
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been made T cell deficient by thymectomy, lethal radiation , 
and bone marrow salvage (TXB). Tumor regression in TXB 
recipients could be blocked by the additional transfer of 
lymphocytes from nonimmune TBA, but not from normal animals. 
Successful transfer of tumor immunity has also been 
demonstrated in recipients which have been pretreated with 
cyclophosphamide (69) or sublethal radiation (46,71,72,103). 
Both procedures are known to decrease Ts cell population. 
North and colleagues (73,74) have further characterized 
the nature of tumor-induced Ts cell generation by showing 
that TBA acquire T cells that can cause regression of small 
tumors in recipients on passive transfer during early growth 
of the tumor (between days 6 and 9). In later tumor growth, 
effector T cell population decreases and the appearance of T 
cells that can suppress adoptive immunity against 
established tumors begins. In contrast, Fujimoto's group 
has shown that Ts cells are generated within 24 hours of 
tumor implant (30). 
Similar results were obtained by Treves and co-workers 
(108,109,110) and Umiel and Trainin (112). They found that 
spleen cells from C57/BL6 mice bearing the 3LL lung tumor 
could inhibit growth of the same tumor in recipient mice if 
the transferred cells were obtained after the injection of 
tumor cells but before the appearance of the tumor in the 
donor mice. If the spleen cells were obtained after the 
appearance of tumors in the donor animals, then transfer 
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resulted in enhanced tumor growth, as well as an increase in 
the number of lung metastases (112). After excision of the 
tumor in the donor animal, spleen cells quickly lost the 
ability to augment tumor growth (109). Treatment with 
anti-theta serum and complement, to deplete spleen cells of 
T cells, resulted in cells that could no longer augment 
tumor growth in recipient animals (110). It was further 
found that the supernatant of incubated immune spleen cells 
could, by itself, on transfer enhance tumor growth; however, 
if immune spleen cells were depleted of T cells and then 
incubated, the supernatant did not enhance tumor growth. 
Supernatant from immune spleen cells depleted of B cells and 
macrophages maintained the ability to enhance tumor growth 
(108 ) . 
The onset of tumor immunity has been associated with 
the presence of helper T cells (Th; 17,18) and cytolytic T 
cells (Tc; 60). Fernandez-Cruz and colleagues have shown 
that tumor immunity may be transferred against established 
murine sarcoma tumors by the selective transfer of Th cells 
to immunocompetent tumor-bearing recipients. North and 
associates have shown that the onset of immunity in the P815 
mastocytoma/TXB recipient system was immediately preceded by 
the production of Tc cells which was significantly greater 
than the production observed in immunocompetent TBA or in 
TXB animals which also received T cells from nonimmune TBA, 
There was no Tc cell production observed in TXB tumor 
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bearing controls. Dye and North (11) also correlated the 
failure of tumor regression in TXB animals receiving 
transfer of nonimmune as well as immune T cells with the 
decreased production of Tc cells. 
The presence of Ts cells capable of inhibiting the 
immune response against malignant cells has also been 
demonstrated in humans. In patients with osteogenic 
sarcoma, it has been shown that the peripheral blood 
lymphocytes of patients without detectable tumor specific 
cytotoxic activity in vitro contain a population of 
lymphocytes which mediate tumor specific cytotoxicity and a 
population of Ts cells that inhibit the in vitro activity of 
the cytotoxic cells. 
Based on the results discussed above and that of 
numerous other groups (5,8,13,22,31,53,54,61,67,89,96,97, 
98,99,104,105), it has been concluded that, in many tumor 
systems, Ts cells develop which are capable of inhibiting 
effector T cell populations and allowing the progressive 
growth of immunogenic tumors. 
Mechanism of Ts Cell Induction 
Exactly how tumors induce the generation of Ts cell is 
not known. A few possible mechanisms have been demonstrated 
in experimental models and are discussed below. 
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The ultraviolet (UV) light-induced spontaneous tumor 
system has been extensively studied and found to be 
associated with the generation of Ts cells. UV-induced 
tumors are highly antigenic and usually rejected in normal 
mice, however, UV-irradiated mice fail to reject these 
tumors (53). Kripke and Fisher (22,54) and Daynes and 
colleagues (8,99) demonstrated that the susceptibility of 
UV-treated mice to UV-induced tumors is an immunological 
phenomenon mediated by lymphocytes. Further study by 
Spellman and Daynes subsequently showed that UV-treated mice 
possess Ts cells, which appear prior to tumor implantation, 
can transfer susceptibility to UV-induced tumors (97), and 
are capable of specifically inhibiting antitumor immune 
responses (98). 
An explanation for the appearance of Ts cells prior to 
tumor cells has been proposed by Greene et al. (40). They 
have demonstrated that UV radiation affects I-A-" antigen 
presenting cells (APC) and prevents ordered antigen 
presentation. The defect in APC function is thought to 
lead to Ts cell generation. It is also possible that I-A 
APC exist which are UV-resistant and preferentially present 
to Ts cells, or that UV radiation alters antigens, such that 
when presented by APC, Ts cells are preferentially induced. 




Another experimental mechanism is the intravenous 
administration of soluble tumor antigens. Since the 
shedding of TAA into the peripheral circulation is known to 
occur (80), this may represent, at least in part, the 
mechanism by which progressive tumors activate Ts cells. 
The condition of "chronic antigen stimulation" may lead to 
the activation of Ts cells that will result in down 
regulation of an antitumor immune response and tolerance. 
Teleologically, it has been suggested that this mechanism 
may have evolved to prevent autoimmune disease; however, in 
tumor-bearing animals and patients this signal may result in 
a situation which favors tumor growth (3). 
As mentioned previously inappropriate presentation of 
tumor antigens by APC has been suggested as a mechanism of 
Ts cell induction. It has been shown that macrophages 
treated with anti-I-A antibody (macrophages are I-A-") 
exclusively generate Ts (80). Based on this observation and 
those in the UV light tumor system, it was proposed that MHC 
class II-restricted antigen presentation is important in the 
induction of Th but not Ts cells, and further, it was 
proposed that Ts cells may have less strict requirements 
than Th cells about the context in which they recognize 
antigen (9,80). This means that tumor antigen presented to 
the immune system by class II™ APC could result in the 
preferential activation of Ts cells. 
* 
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Mechanism of Ts Cell Action 
In some systems Ts cells that inhibit the rejection of 
tumors in immunized mice have been shown to be specific 
(12) and produce tumor-specific soluble factors with 
immunosuppressive activity (T suppressor factor, TsF; 38). 
It has been demonstrated that suppression, by Ts cells and 
their factors, in conventional systems occurs through an 
interference with the development of Th cells specific for 
the antigen or directly by interaction with Th or B cells 
(6,35,100). Although the mechanisms are not clear, Ts cells 
also interfere with Tc cell (24), NK cell (47) and 
macrophage (86) activity, and probably that of inflammatory 
cells (i.e. CD4-~ T cells involved in inflammation; 59). It 
is likely that tumor-induced Ts cells down regulate the 
immune response to tumors in a similar fashion. 
The important role of Ts cells in the regulation of the 
host immune response to tumor antigen suggests that these 
cells are reasonable targets to block tumor-mediated 
suppression. This thought has led to the study of tumor 
therapy with anti-Ts cell protocols, which will be discussed 
in the next section. 
It should be noted that there also exist in TBA non-T 
suppressor cell which are capable of inhibiting immune 
responses (reviewed in 5,67). These cells, which include 
macrophages and B cells, are capable of nonspecific 
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suppression of the immune system and may be important in 
some tumor systems. 
Immunotherapy in the Treatment of Cancer 
The current treatment of cancer primarily consists of 
surgery, radiation therapy, and/or chemotherapy. Any side 
effects of treatment on lymphoid cells and the immune 
response have been accepted as necessary. Immunotherapy or 
augmentation of the host's own immune response is now 
considered the emerging fourth modality of cancer treatment 
(71,78). 
Nonspecific Immunostimulation 
Various methods of nonspecifically stimulating an 
animal's or patient's immune response have been tried. For 
example, inoculation of tumor with the bacterial antigens, 
BCG (an attenuated form of mycobacterium) and C. parvum 
leads to an immune response which results in the destruction 
of intracellular antigen and also an increase in the number 
and activity of macrophage and NK cells (71). Increased 
numbers of these cells often leads to enhanced tumor 
destruction as well. Unfortunately, these methods are 

18 
limited to accessible tumors and have met with minimal 
clinical success (90). 
Antitumor Monoclonal Antibodies 
Since the development of the hybridoma technique by 
Kohler and Milstein in 1975 (51), a more promising 
anticancer approach has been the use of tumor-specific mAbs 
(reviewed in 58). Monoclonal antibodies directed against 
TAA can be used through their direct antitumor effect or 
through the targeting of chemotherapeutic or other cytocidal 
agents with mAb-antitumor agent complexes. Clinical 
successes with mAb therapy have been achieved but so far 
have also been limited and difficult to reproduce. 
Adoptive Immunotherapy 
Numerous attempts to specifically increase the 
intensity of antitumor responses have been made with 
adoptive immunotherapy (reviewed in 90,92). In this 
approach tumor- sensitized lymphocytes are transferred to a 
tumor-bearing host and mediate either directly or indirectly 
an immune response against the tumor. Although transfer of 
immune cells usually inhibits the growth of tumor implants, 
tumor growth has sometimes been enhanced (104). In some 
cases the transfer of cells results in autoimmune disease (7) 
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Until recently, most successes with adoptive therapy have 
either been with tumor implants or small tumor burdens, or 
depended on the elimination of host Ts cells prior to 
transfer (91). For example, North and his associates have 
shown that combination therapy with cyclophosphamide and 
immune spleen cells caused the complete regression of 
established tumors in all mice, while spleen cells alone had 
no effect (69). It was also noted that cyclophosphamide 
alone caused a temporary halt in tumor growth. 
Adoptive Immunotherapy with Interleukin-2 (IL-2) 
With the discovery of T cell Growth Factor or IL-2 
(94), adoptive immunotherapy of established tumors has been 
more successful. IL-2 which is known to amplify and 
activate lymphocytes (lymphokine-activated killer cells, 
LAK) is a most promising anticancer agent. In rodent 
experiments, combination of LAK cells and purified IL-2, has 
been shown to cause regression of established pulmonary and 
hepatic metastases for a variety of tumors (55,63,64). 
Based on these models, Rosenberg and colleagues (91) have 
used autologous LAK cells with IL-2 (in culture and in vivo) 
to produce partial to complete remission in approximately 
forty-five percent of patients with advanced cancer. It 
should be noted that these patients had failed standard 
therapy. Best results were obtained with the following 
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cancers: metastatic melanoma, colorectal carcinoma, renal 
cell cancer, and adenocarcinoma of the lung--all of which 
are fairly resistant to therapy with conventional agents. 
Anti-Ts cell Therapy 
Ts cells inhibit the efficacy of host effector 
responses against certain tumors. Thus decreasing or 
eliminating Ts cells and their factors is a rational 
approach to the treatment of malignancies suspected of 
inducing immune suppression. 
It is likely, in fact, that the success of certain 
conventional treatment regimens partly depends on 
elimination of Ts cell activity. Cyclophosphamide (Cytoxan) 
is one of the most effective chemotherapeutic agents 
available and has been shown to decrease Ts cell activity 
(44,69). Irradiation, another clinically useful modality, 
is also known to potentiate certain in vivo immune responses 
by diminishing Ts cell activity (46,71,110). Ts cells may 
have a short lifespan and/or be dependent on tumor load. If 
this is the case, then tumor excision (surgery) may decrease 
Ts cells and result in more effective antitumor responses 
( 3 ) . 
The importance of the T cell system as a whole to host 
defenses against neoplasia, as well as microorganisms, 
should be emphasized. Regimens that nonselectively impair 
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overall T cell function may result in life threatening 
situations due to immune compromise, such as overwhelming 
infection, and not necessarily increase survival of a tumor- 
bearing host. 
One study which has shown the importance of selectively 
inhibiting Ts cell activity was conducted by Greene et al. 
(39). Anti-thymocyte serum (ATS) when administered to 
syngeneic mice between day 0 and day 1 after tumor 
implantation enhanced tumor growth, while ATS given between 
day 3 and day 10 reduced tumor growth. This discrepancy was 
thought to be due to nonspecific T cell destruction and a 
reflection of which T cell population predominated at each 
point of tumor growth, Th, Tc, or Ts. Other studies have 
tested the following treatments which may preferentially 
eliminate Ts cells but still affect other immune cell 
populations: splenectomy (16), splenic irradiation (16), 
low dose cyclophosphamide (44,69), low dose irradiation 
(72), adult thymectomy (89), and anti-I-J sera and antibody 
(10,36). 
Using the most selective of these regimens, monoclonal 
anti-I-J antibody, Greene's group has shown that daily 
treatment with nanogram doses i.v. results in the 
significant suppression of growth of the MCA-induced S1590a 
and Sal syngeneic tumors in A/Jax mice (10). Histological 
exam of treated TBA revealed substantial infiltration and 
necrosis of tumors compared to control TBA. It was further 
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shown that spleens from TBA could no longer enhance tumor 
growth on transfer to immune tumor-bearing recipients if the 
cells were first treated with anti-I-J antibody. 
When the I-J subregion was initially characterized and 
Greene's study was published it was believed that the 
subregion was uniquely associated with Ts cells and factors 
(66,81,82,102). However, it has subsequently been shown 
that the subregion serologically defines other T cell 
regulatory activities as well. It is now known that I-J 
determinants are expressed on Th cells (57,101), augmenting 
T cells (76), contrasuppressor T cells (Tcs,116), and 
macrophage (68), as well as Ts cells. 
Further studies with anti-I-J reagents have shown that 
leukemic cell growth is enhanced and mortality increases in 
syngeneic mice (57). It is thought that the enhancement of 
tumor growth is due to interference of a humoral response 
which is under the control of an I-J- Th cell. Recall that 
humoral immunity is important in host defenses against 
leukemia. Other groups have also shown that I-J" cells are 
necessary for the adoptive transfer of syngeneic tumor 
immunity (28). 
The initial excitement over therapy with anti-I-J 
antibody has now passed, but a monoclonal antibody raised 
specifically against T cell suppressor factor has been 
described recently by Ferguson et al. (19). This mAb 
called 14-12 is able to block the activity of Ts cells and 
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TsF of various genetic and antigenic specificities in vitro 
(19), and is known not to bind to Th, Tc, Tcs, APC, or B 
cells by negative or positive selection techniques (Horvat, 
B., Flood, P.M. unpublished results). The current study was 
designed to evaluate the effect of mAb 14-12 on tumor growth 
in vivo. 

MATERIALS AND METHODS 
Mice: 6-10 week old C3H/HeN (mammary tumor virus negative, 
MTV-) mice from colonies of germ-free derived specific path¬ 
ogen free (SPF) animals were obtained from the Frederick 
Cancer Research Center, NCI, Frederick, Maryland. In all 
therapeutic experiments each group consisted of at least 5 
mice. 
Fibrosarcoma Line: The fibrosarcoma 3162-PRO is a 
nonmetastatic tumor which kills by infiltration of vital 
organs and tumor load. This tumor was previously induced in 
UV-irradiated C3H/HeN (MTV-) mice by subcutaneous injection 
of 3-methylcholanthrene under the ventral non-UV exposed 
skin (65). Tumor cells were maintained in vitro in 
Dulbecco's Modified Eagles Medium (DMEM; GIBCO, Grand 
Island, NY) supplemented with 10% heat inactivated fetal 
calf serum (FCS), 2 mM 1-glutamine, 50U/ml penicillin, and 
50 ug/ml streptomycin (GIBCO). 
Preparation and Transplantation of 3152-PRO: For tumor 
challenges, cells were grown in vitro and taken during late 
log phase growth. Tumor cells were washed three times in 
Hank's Balanced Salt Solution (HBSS; Flow Laboratories, 
McLean, Va). Cells (1 x 10^) were injected subcutaneously 




back of challenged animals. All mice were injected at the 
same time and then randomly divided into experimental 
groups. 
Measurement of Tumor Size: Tumor growth was measured 
macroscopically using a vernier caliper by measuring the 
longest diameter of two perpendicular measurements of the 
tumor mass to calculate tumor area. This method has been 
shown to correlate with tumor weight (36). The tumors were 
examined once a week independently by two investigators 
during the course of the experiments. Animals with tumors 
greater than 1mm3 (the size at which a mass can be easily 
detected by palpation of skin at the site of tumor 
injection) designated tumor bearing ani_mals (TBA). 
Monoclonal Antibodies: The monoclonal anti-suppressor T 
cell antibody was previously generated as described by 
Ferguson et al. (19). Briefly, rats were immunized with 
lOOug of purified T suppressor factor (TsF) isolated from 
the serum of mice hyperjjnmunized to sheep red blood cells 
(SRBC). Spleen cells from rats immunized with TsF were 
fused with Y-3Ag 1.2.3, a hypoxanthine-aminopterin-thymidine 
(HAT)-sensitive (i.e. hypoxanthine guaninephosphoribosyl- 
transferase deficient) rat myeloma, producing an IgM 
monoclonal antibody of unknown specificity. Positive 
hybridomas were chosen based on their ability to bind 
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purified immunogen in an enzyme linked immunosorbent assay 
(ELISA), and cloned by limiting dilution. 
The 14-12 monoclonal antibody (mAb) has been shown to 
be sensitive to and specific for suppressor effector T cells 
and factor of a number of different antigenic and genetic 
specificities (19). This antibody can be used to eliminate 
suppressor effector T cell activity in vivo (20,21,88). 
Antibody Y3Ag, produced by the myeloma parent used in the 
fusion to generate 14-12, has no demonstrable effect on 
suppressor T cells or factors (19). Antibody Y3Ag was used 
for control rat IgM in some experiments and was prepared 
identically to serum-free mAb 14-12. 
Preparation of mAb 14-12 for injection: Purified serum- 
free antibody was obtained by growing 14-12 cells in vitro 
in Iscove’s serum free medium (GIBCO, Grand Island, New 
York) containing only gentamicin, insulin, progesterone, 
transferrin, and trace metals as described by Mosier (62). 
MAb 14-12 was seeded at 1CP cells/ml and grown to 
confluency in medium. Cell supernatant was cleared by 
centrifugation and passage through a sterile 0.2 urn filter 
(Millipore/Continental Water Systems, Bedford, MA). The 
antibody was precipitated by a 45% cut of saturated ammonium 
sulfate (SAS). The precipitate was redissolved in PBS and 
dialyzed against PBS. Purified antibody showed only an IgM 
heavy chain and a K light chain in SDS PAGE under reducing 
conditions (gel not shown). Antibody concentration was 
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determined by ELISA and optical density spectrophotometry at 
wavelength 280nm. 
Antibody from ascites fluid was prepared by injecting 
107 hybridoma cells intraperitoneally into mice which had 
been pretreated with pristane 3 weeks prior. Twenty-four 
hours prior to injection with hybridoma cells the animals 
were injected with 0.1 ml of rabbit anti-thymocyte serum 
subcutaneously. On the day of injection mice received 500 
rads of irradiation and were then injected with hybridoma 
cells. Ascites fluid was harvested after 5-7 days and was 
purified in an identical fashion to the serum-free mAb. 
Treatment with mAb 14-12: In therapy experiments, 
injections of 0.05 ml containing a given dose of antibody 
were injected either intravenously, intraperitoneally, or 
intradermally at the site of tumor injection three times a 
week, one ti_me a week, or once as noted. 
Antigens: 2,4,6-Trinitroben2ene sulfonate (TNBS) was 
obtained from Sigma Chemical Company (St. Louis, MO). 
2,4,6-Trinitro-1-chlorobenzene or Picryl Chloride (PCI) was 
obtained from the Eastman Chemical Company (Smithtown, NY). 
Preparation of Spleen Cells: Spleens were aseptically 
removed from mice killed by cervical dislocation. Spleen 
cells were gently teased apart from fibrous tissue in HBSS 
and centrifuged at 500 x G for 5 minutes. Spleen cells were 
' 
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washed twice with HESS and resuspended in HBSS. Further 
preparation was as described below. 
Preparation of Contrasuppressor T cell-deficient Spleen 
Cells: The I-J encoded determinant of contrasuppressor T 
cells is recognized by the monoclonal anti-I-J reagent 4B-11 
which distinguishes from the I-J determinant found on Ts 
cells (116). Anti-I-J 4B-11 was kindly provided by Dr. 
Charles Janeway, Yale University School of Medicine, New 
Haven, CT. Spleen cells (1 x 107 cells/ml) prepared as 
described above were incubated with anti-I-J (diluted 1:1000 
in HBSS) at room temperature for 30 minutes. After 
centrifugation at 500 x G for 5 minutes, spleen cells were 
resuspended in HBSS. Rabbit serum (Pel-Freez, Rogers, AK; 
diluted 1:10 in HBSS), used as a source of complement, was 
then added in an equal volume to the spleen cells. The 
preparation was incubated at 37r-' C for 30 minutes. Cells 
were then washed three times with HBSS and resuspended in 
HBSS. 
Preparation of Hapten-modified Spleen Cells: Spleen 
cells prepared as described above were trinitrophenylated 
(TNP-) at room temperature for 10 minutes in PBS (pH 7.2) 
containing 3mM TNBS. The TNP-spleen cells were washed three 
times with HBSS and resuspended in HBSS. 
Adoptive Transfer of Contact Sensitivity and Treatment with 
mAb 14-12: Donor mice were immunized with 5% PCI in 
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ethanol:acetone (3:1) by painting shaved abdomens (0.20 ml) 
and placing a drop on each paw (2). Four days later these 
mice were sacrificed and spleens were removed and treated 
with a monoclonal anti-I-J reagent (described above) to 
eliminate contrasuppressor T cells which would affect Ts 
cell activity (88). Anti-I-J-treated spleen cells (3 x 
107) were transferred by intravenous injection to a second 
set of mice which had been primed on the previous day with 
14-12 (lOug) or PBS (control). Recipients were immunized 
immediately with 1% PCI in olive oil on the right ear. 
Contact sensitivity response was measured 24 hours later as 
described below. 
Tolerance Induction and Treatment with mAb 14-12: On day 0 
mice were pretreated with 1) nothing, 2) PBS, or 3) 14-12 
(10 ug). On day 1 some groups of mice were immunized with 2 
x IQ-7 TNP-spleen cells intravenously. Four days later all 
mice were immunized with 1% PCI in olive oil on the right 
ear. Contact sensitivity response was measured 24 hours 
later as described below. 
Measurement of Contact Sensitivity: The contact sensitivity 
response was determined by measuring ear swelling with an 
engineer's micrometer. Each ear was measured in triplicate 
in a "blind" protocol. All contact sensitivity values are 
expressed as units of swelling as determined by the differ- 
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ence of the left ear (unchallenged) vs the right ear 
(challenged). 1 unit = 10"3 cm. 
Statistical Analysis: Data are reported as Mean values + 
S.E.M. Analysis of data was performed using the Student's t 
test with 95% confidence intervals. 

RESULTS 
Treatment with MAb 14-12 Affects the Progressive growth of 
the Murine Fibrosarcoma 3152-PRO. 
MAb 14-12 Inhibits Tumor Growth and Decreases Tumor 
Incidence. 
Normal age-matched C3H/HeN mice were transplanted with 
3152-PRO tumor cells as described above. Immediately after 
transplantation, animals were put into a therapeutic regimen 
of three times a week, one time a week, or single injections 
of 100 ug of mAb 14-12 (prepared from serum-free (SF) 
media). The results in Table I show the ability of mAb 14- 
12 to inhibit tumor growth. Control animals injected with 
3152-PRO tumor cells all developed sizeable tumors within 3 
weeks. Animals transplanted with 3152-PRO tumor cells and 
injected with single doses or weekly injections of mAb 14-12 
showed little or no reduction of tumor incidence. However, 
animals transplanted with tumor cells and given three 
injections a week of mAb 14-12 showed a greatly reduced 
incidence of tumor. This effect was not observed in animals 
given identical therapeutic regimens of mAb Y3Ag, a 
/ 




In similar experiments the rate of tumor growth was 
quantified weekly by physical measurement of tumors. Figure 
1 shows that injections 3 times a week of 10 ug of mAb 14-12 
(prepared from ascites) significantly inhibited (week 1 
p < 0.001, weeks 2 and 4 p < 0.01, week 3 p < 0.02) tumor 
growth as early as day 7 after tumor inoculation. This 
effect persisted for at least 28 days which was the duration 
of therapy. In this experiment mAb therapy resulted in 
greatly reduced incidence of tumor as well. All control 
animals (n=5) developed palpable tumors by week 1; whereas 
only one treatment animal (n=5) had developed a tumor by 
week 4. Animals that resisted a challenge of 3152-PRO tumor 
by treatment showed no evidence of tumor even four months 
after the termination of treatment. 
The ReEimen and Route of Administration of MAb 14-12 is 
Critical. 
Experiments were also done to test various methods of 
administering the mAb 14-12. As previously mentioned, most 
significant inhibition of tumor growth was obtained with 
therapeutic regimens of repeated injections 3 times a week 
as opposed to once a week or single injections (Table I; 
Figure 2). As shown in figure 2 the route of immunization 
was also found to be critical. Best results were obtained 
with intraperitoneal (i.p.) or intratumor (i.t.) injections. 
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Treatment with mAb 14-12 by i.p. or i.t. routes three times 
a week resulted in the complete inhibition of tumor growth. 
Again all control animals (n=5) developed palpable tumors by 
week 1, but no treatment animal showed evidence of tumor for 
greater than 4 months after termination of treatment. 
Intravenous (i.v.) injection also significantly decreased 
tumor growth by week 4 (wk 3 p < 0.05, week 4 p < 0.01), but 
was not as effective as i.p. or i.t. routes. Four of five 
animals in the i.v. group developed tumors by week 2. 
The Effect of MAb 14-12 is Dose-related. 
The results in Figure 3 reveal that animals treated 
with mAb 14-12 (prepared from SF media) 3 times a week 
demonstrate a dose response. The maximum dose tested was 
10 ug/injection. This dose was chosen because it had been 
effective in previous studies of mAb 14-12 (20). Treatment 
with 10 ug/injection was most effective and was 
statistically significant (p < 0.01) by week 3. Treatment 
groups receiving smaller doses of mAb 14-12 had subsequently 
larger mean tumor sizes. At lowest doses of mAb the 
treatment groups developed larger tumors than those that 
developed in control animals (discussed in next section). 
It should be pointed out that although tumors grew slower in 
treatment groups (except group receiving 0.01 ug/injection), 
by week 3 all mice had developed tumors. 
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Augmentation of Tumor Grovrth. 
As mentioned above, another interesting phenomenon may 
be seen in the dose response curve (Figure 3). Groups of 
animals treated with low doses of mAb 14-12 (i.e. 0.1 
ug/injection or less) actually had slightly larger mean 
tumor sizes and higher tumor growth rates than did the 
control group given identical regimens of saline 
injections. In fact, by day 28 all animals (n=5) in the 
group receiving 0.01 ug/injection had succumbed to tumors 
that on the average were significantly larger than control 
tumors (p < 0.01). 
The phenomenon of tumor augmentation was also seen when 
the 3152-PRO tumor grew poorly in the control animals. For 
example. Table II shows that no animals in either control or 
treatment groups had developed tumors by week 1. By week 2 
tumors began to develop in treatment animals (2/5), but no 
control animal developed a tumor until week 5. Mean tumor 
size was significantly different at the p < 0.02 level by 
week 5. It is interesting to note that in this experiment, 
treatment with mAb 14-12 not only increased the mean tumor 
size of the group of animals, but also the number of tumor¬ 
bearing animals per group by week 5 (Control 1/5; Treatment 
5/5 ) . 
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Monoclonal Antibody 14-12 Selectively Blocks Ts Cell Action. 
The Suppression of the Adoptive Transfer of Contact 
Sensitivity to PCL is Blocked in Animals Treated with 
MAb 14-12. 
It has previously been shown that animals painted with 
picryl chloride (PCI) show a strong contact sensitivity (CS) 
reaction on reapplication of the same or a cross-reacting 
agent such as trinitrophenol (TNP; 87). This antigen- 
specific CS reaction can be adoptively transferred by immune 
spleen cells into naive recipients. It is also known that 
the transfer of CS can be suppressed by an antigen-specific 
Ts factor, TNP-TsF (93). The transfer of CS requires at 
least 2 distinct T cell populations, an Lyl + I-J Vicia 
villosa nonadherent (VV-) DTH effector T (Tdth) cell, and an 
Lyl + I-J" W adherent (W+) contrasuppressor T (Tcs) cell 
(48,88). Depletion of either cell type blocks the adoptive 
transfer. The Torn effector cell can only transfer antigen- 
specific CS to naive animals in the presence of the Tcs 
cell, which "protects" the effector cell from host 
suppressor mechanisms (i.e. TNP-TsF), or in the absence of 
Tcs cells if host suppressor mechanisms are compromised. 
For example, treatment of animals with cyclophosphamide, 
which has been shown to overcome Ts cel1-mediated 
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mechanisms (48), allows the Tdth cell alone to transfer CS 
( 88 ) . 
Figure 4 shows the results of an adoptive transfer 
study in which normal age-matched C3H/HeN mice were 
pretreated with PBS or 10 ug mAb 14-12 on day 0. On day 1 
groups C and D received syngeneic immune spleen cells from 
mice which had been sensitized 4 days earlier by skin 
painting. In order to selectively eliminate Tcs cells the 
immune spleen cells were treated with anti-I-J prior to 
transfer. CS response was determined as described in 
Materials and Methods. It can be seen that the mice which 
were pretreated with mAb 14-12 and received anti-I-J treated 
immune cells (group D) developed a CS response which was 
significantly different (p < 0.001) from mice which received 
no immune cells (Groups A and B) or no mAb (Group C). 
Nonspecific effects of mAb 14-12 were controlled for in 
group B which received antibody but no immune spleen cells. 
Treatment with antibody alone had no effect on CS response 
when compared to the control animals (Group A). The fact 
that elimination of Tcs cells and treatment with mAb 14-12 
resulted in the transfer of CS suggests that mAb 14-12 
interferes with the action or generation of Ts cells and 
does not affect other immune cell populations such as the 
Tdth effector cell. 
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Tolerance Induction to TNP is Blocked and Converted to an 
Immunogenic Signal in Animals Treated with MAb 14-12. 
Tolerance to an antigen such as TNP can be induced by 
injecting syngeneic hapten-conjugated spleen cells (TNP-SC) 
intravenously (111). The tolerizing signal is very potent 
and can be given even after subcutaneous injection (which 
immunizes for a CS response rather than tolerance). It has 
been well established that this tolerizing signal is 
mediated by antigen specific Ts (111). 
Figure 5 reveals that C3H/HeN mice, which were injected 
with mAb 14-12 prior to i.v. TNP-SC transfer, developed a CS 
response rather than tolerance. The response observed was 
significantly different (p << 0.001) from that observed in 
controls. Animals receiving a tolerance-inducing protocol 
but no mAb 14-12 (Groups D and E) did develop tolerance as 
evidenced by CS responses which were similar to control 
animals (Groups A and B). Group C which consisted of 
animals primed with mAb 14-12 but not immunized with TNP-SC 
again reveals that mAb 14-12 had no nonspecific effects on 
the CS response. These results show that treatment with mAb 
14-12 converts a normally tolerogenic signal (i.v. TNP-SC) 
to an immunogenic one. The hypothesis that mAb 14-12 
selectively interferes with 7 Ts cell action is again 
supported by this data. 

DISCUSSION 
The present study has shown that in vivo treatment with 
mAb 14-12 specifically interferes with Ts cell activity and 
not with the activity of effector T cell populations. MAb 
treatment allowed the transfer of a contact sensitivity 
response to PCI with Tcs cell-deficient immunized spleen 
cells. Under these conditions the transfer of CS, which is 
mediated by a DTH effector T cell, is normally blocked by Ts 
cells in untreated recipients. Treatment with mAb 14-12 
also converted a Ts cell-mediated tolerogenic signal (i.v. 
TNP-SC) to an immunogenic one which again requires an 
effector T cell. In both cases, mAb 14-12 alone had no 
nonspecific augmenting effect on the immune response. Other 
studies have shown that mAb 14-12 does not interact with Th, 
Tc, APC, or B cells in vitro (Horvat, B., Flood, P.M. 
unpublished results). These results suggest that mAb 14-12 
can alter Ts cell activity in vivo with profound 
consequences on immunity to many antigenic systems including 
tumors. 
The effect of mAb 14-12 on tumor growth was studied and 
it was shown that treatment with this antibody can 
significantly inhibit d:he growth of a highly progressive 
murine fibrosarcoma in syngeneic animals. As expected, more 




on tumor growth than does less frequent administration. The 
effect of treatment with mAb 14-12 was also found to be 
dose-related with 10 ug three times a week being most 
effective. The effectiveness of this dose correlates well 
with subsequent in vivo studies of mAb 14-12 (20,21). 
Although 10 ug was the highest dose tested in this study, 
other studies have not found higher doses to have a greater 
effect (20). The fact that the inhibitory effect of 
purified mAb 14-12 was found to be dose-related and 
dependent on the frequency of administration strongly 
suggests that the effect of treatment was antibody-mediated 
and not related to other factors such as stress of 
injection, immunological or disease state of the animals, or 
the diluent. 
The route of administration was also found to effect 
outcome of treatment. Intratumor and i.p. routes were most 
effective, while i.v. therapy was less effective. This 
result may be artifactual as i.v. injection into the 
retroorbital plexus is technically a more difficult form of 
administration, and thus, a full dose of antibody may not 
have been delivered at every injection. Another possible 
explanation is that i.v. administration results in a more 
rapid clearance of antibody and therefore has a diminished 
effect. 
The mechanism by which mAb 14-12 interferes with the 
suppressor cell circuit is uncertain but several mechanisms 
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are possible. The fact that mAb 14-12 reacts with Ts cells 
and TsF of different antigenic and genetic specificities 
(19), combined with the knowledge that Ts cells have been 
shown to act through an anti-idiotype mechanism in some 
systems (24 ) , suggests that the antibody may interact with 
cells through an idiotype mechanism. The antibody may bind 
to Ts cells, TsF, or a subfactor and prevent the interaction 
of these cells or molecules with Th cells or other effector 
T cells. Alternatively, mAb 14-12 may bind to immature 
suppressor cells and prevent the differentiation to 
functional Ts cells. As mAb 14-12 is an IgM molecule, if 
bound to Ts cells, it could also initiate complement 
mediated lysis. 
The results presented here, together with those of 
earlier experiments have demonstrated the importance of Ts 
cells and factor in the regulation of the immune response to 
tumors and the usefulness of an antibody specific for Ts 
cells in the study of regulatory T cell circuits. The 
success of tumor therapy with mAb 14-12 supports the 
hypothesis that selective interference with Ts cells allows 
a host to mount a more effective immune response resulting 
in increased tumor resistance. 
Additional studies with mAb 14-12 have recently shown 
that, used in combination with IL-2, it could cause 60 to 90 
percent reduction of established pulmonary metastases of the 
weakly immunogenic MCA-induced fibrosarcoma 106 (49). 
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Combination therapy was more effective than either agent 
alone. The finding that mAb 14-12 had no detectable 
antitumor activity when used by itself was thought to 
reflect an inadequate immune response to the tumor used even 
without suppression by Ts cells. 
Application of therapy to other tumors with mAbs 
similar to 14-12 needs to be carefully studied. In the 
present study an IgM mAb to Ts cells was used; however for 
several reasons an IgG antibody would probably be more 
effective. IgG antibodies have higher affinity for 
idiotype* material than do IgM antibodies. IgG molecules 
are more able to cross endothelial barriers (due to smaller 
size), and thus would have access to more body compartments. 
While both molecules are able to fix complement, only IgG 
can activate antibody-dependent cell-mediated cytotoxicity 
responses (113). IgG anti-suppressor mAbs have recently 
been synthesized and are currently undergoing investigation 
with conventional antigen and tumor systems. 
The findings of this study are potentially very 
exciting. As more is learned about immunoregulation and 
tumor immunity it becomes more possible to treat cancer. 
Immunotherapy may be more effective if Ts cells as well as 
tumor cells are targeted by the treatment. Eventually tumor 
therapy may include a mAb directed at Ts cells in humans, or 
the combination of such an antibody with other antitumor 
agents or with the transfer of immune cells and IL-2. 
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Several problems that may interfere with the use of mAh 
14-12 or another similar antibody against Ts cells should be 
mentioned. These include the development of autoimmunity 
due to lack of Ts cells to down-regulate the immune 
response. MAb 14-12 blocks Ts cells of various 
specificities. But if an antibody could be produced that 
reacted to antigen- or tumor-specific Ts cells only, then 
autoimmunity would not be a problem. 
Another potential problem arises with the use of murine 
mAbs in humans. The development of allergic responses 
characterized by fever, chills, dyspnea, and anaphylactoid 
reactions has been reported in some patients who have been 
treated with murine antibodies (56). In these patients 
circulating antibodies to mouse Ig (mlg) could be detected 
and were sometimes associated with diminished clinical 
response (56,95). Thus, in addition to allergic responses, 
it appears that antibodies develop to mouse Ig which inhibit 
therapeutic efficacy. Several methods could potentially be 
implemented to avoid these problems--development of human 
mAb, induction of tolerance to mouse Ig, or the development 
of mAb coupled to cytotoxic agents (cells interacting with 
mlg would then be destroyed and no immune response to mlg 
would develop). Another solution may be the use of hybrid 
antibodies. Recombinant technology has been used to 
synthesize mAbs that combine the specificity of mouse 

V-regions with human C-regions (50). In theory, these 
hybrid antibodies should be less immunogenic. 
In the present study another phenomenon, that of 
augmentation of tumor growth, was also observed in mice 
treated with mAb 14-12. This effect was observed with low 
doses of mAb (i.e. 0.1 ug or less) and when tumors grew 
poorly in controls. This result may have been spurious, but 
the facts that the effect was dose-related in some cases and 
all animals within a treatment group behaved the same 
suggests that some common factor was affecting each member 
of the group. Experiments were designed to control for the 
stress of injection, stock of mAb, and the age of animals; 
however, some important factors were not controlled--immune 
or disease state of animals and phenotypic alterations in 
tumor cells. 
Disease state of animals can effect immune function 
including tumor rejection. Animals were specific pathogen 
free when obtained from the supplier, but at any time during 
experiments some animals may have been infected by a virus 
or other pathogen. Diseased animals may be unable to mount 
a significant immune response even in the absence of Ts 
cells. Perhaps macrophages or other immune cell populations 
have decreased function in diseased animals. Non-infected 
control animals may then mount relatively more effective 
immune responses even in the presence of Ts cells. The 
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concept of an insufficiently activated immune response will 
be further discussed below. 
With long term passage of tumors phenotypic alterations 
in tumor cells occur. In this study, tumor cells were 
always harvested during late log phase growth, but the 
number of serial passages from cryopreserved samples was not 
controlled. It is possible that the tumor became less 
immunogenic during serial passage. Decreased immunogenicity 
would make the tumor cells less susceptible to immune 
rejection. In experimental systems, increasing the 
immunogenicity of tumors has been shown to result in 
increased Tcs cell populations and enhanced tumor rejection 
(23,26). Although speculative, the Tcs cells are thought to 
be junportant in tumor rejection because they protect 
effector T cells from suppression by Ts cells (26,32,37). 
If decreasing immunogenicity results in decreased Tcs cell 
populations, the immune response to a less immunogenic tumor 
may be more susceptible to suppression by Ts cells. 
Phenotypic alterations may also result in tumors that can 
cause more potent induction of Ts cells. MAb 14-12 may not 
be as effective at blocking Ts cell activity under these 
conditions. 
Other explanations are possible for the tumor 
augmentation observed with mAb 14-12. Low doses of mAb may 
stimulate Ts cells while higher doses inhibit their 
activity. Under certain conditions anti-idiotype reagents 

4 5 
are able to stimulate lymphocyte clones expressing the 
idiotype. This has been shown in some B cell systems 
(15,107). Perhaps low doses of mAb or the induction of Ts 
cells by tumors with impaired viability or in suboptimal 
doses may result in conditions such that an anti-idiotype 
reaction between mAb 14-12 and Ts cells augments Ts cell 
activity. 
Also, , Ts cells may have both positive and negative 
effects on tumor growth. In addition to mediating 
suppression, Ts cells may secrete lymphocyte inhibitory 
factors (such as lymphotoxin) or tumor growth factors. It 
has been shown that lymphotoxin, which is usually 
cytocidal, can stimulate protein synthesis in target cells 
at low doses (52). Under certain conditions (e.g. sub- 
optimal tumor challenge or low dose of antibody), mAb 14-12 
may block cell-mediated suppression but not secretion of 
such factors. These conditions could result in increased 
tumor growth. 
An alternative explanation for the observed tumor 
augmentation effect is that while mAb 14-12 blocks 
suppression, it does not directly activate the immune 
system. MAb 14-12 treatment may be more effective when 
combined with immune stimulation regimens. In the future it 
will be interesting to study whether the effect of tumor 
augmentation can be abolished if IL-2 (with or without LAK 
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cell transfer) is used in combination with an anti¬ 
suppressor cell antibody. 
Regardless of the mechanism by which tumor growth was 
augmented in some experiments, this phenomenon needs to be 
investigated in more detail. Additional study may help to 
further characterize regulatory T cell circuits and the 
immune response to tumors. 
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Table I. The effect of monoclonal antibody 14-12 and the 












Control (0 ) 10/10 10/10 
1 total 10/10 10/10 
1 inj/wk 9/10 10/10 
3 inj/wk 2/10 10/10 
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Table II. The augmentation of tumor growth is seen in 
animals treated with mAb 14-12 when tumors grow poorly in 
controls. 
Time Tumor Growth (TBA/Challeneed Animals) 









15 + 15 (1/5) 
0 (0/5) 
0.4 (2/5) 
18 + 18 (2/5 ) 
109 + 28 (5/5) 


Figure l.--The Inhibitory Effect of MAb 14-12 on the Growth 
of a Murine Fibrosarcoma in Syngeneic Mice. Growth curves of 
the MCA-induced 31-52PRO tumor in control (saline) and in 
treatment (lOug mAb 14-12 (ascites) i.p. 3X/wk) animals 
reveal the ability of mAb 14-12 to significantly reduce tumor 
growth as early as day 7 after tumor inoculation (p < 0.001). 
This effect persisted for the duration of the experiment (wk 
2 and 4 p < 0.01; wk 3 p < 0.02). All treated animals which 
resisted a challenge of tumor cells showed no evidence of 
tumor four months after termination of treatment. 
TBA/Challenged animals by week 4: Control 5/5, Treatment 
1/5. 
Mice were challenged with 10v cells 31-52PRO tumor cells 
s.q. on day 0 and tumor size was measured weekly by 
calculating tumor area. Tumor size for each group (n=5) is 
expressed as mean tumor area + S.E.M. Statistical 
differences between experimental and control groups was 




Figure 2.--The Route and Frequency of Administration of MAb 
14-12 are Critical. The inhibitory effect of SF mAb 14-12 
(lOug 3X/wk) on the growth of the MCA-induced 31-52PRO tumor 
was greatest when the antibody was administered i.p. or i.t. 
for 4 weeks (wk 2 p < 0.01; wk 3 p < 0.001; wk 4 p << 0.001). 
Treatment i.v. for 4 weeks (wk 4 p < 0.01) or i.p. for only 
one week (N.S.) also inhibited tumor growth but was not as 
effective. Animals which completely resisted a challenge of 
tumor cells by treatment showed no macroscopic evidence of 
tumor even 4 months after termination of treatment. 
TBA/Challenged animals by week 4: control 5/5, i.v. and i.p. 
(1 wk) 4/5, i.t. and i.p. (4 wks) 0/5. 
Note--Growth curves for the i.t.- and i.p.- (4 wks) treated 
animals are superimposed on the x-axis. 
Mice were challenged with 107 cells 31-52PRO tumor cells 
s.q. on day 0 and tumor size was measured weekly by 
calculating tumor area. Tumor size for each group (n=5) is 
expressed as mean tumor area + S.E.M. Statistical 
differences between experimental and control groups was 




Figure 3.--The Effect of MAb 14-12 on the Growth of a Murine 
Fibrosarcoma is Dose-Related. Growth curves of the MCA- 
induced 31-52PRO tumor reveal that treatment with lOug SF 
mAb 14-12 i.p. (3X/wk) was most effective and significantly 
inhibited tumor growth (wk 3 and 4 p < 0.01). Treatment with 
low doses (i.e. 0.lug or less) resulted in augmentation of 
tumor growth. This augmentation effect was statistically 
significant by wk 4 (p < 0.01) in animals receiving 
O.Olug/inj. TBA/Challenged animals by week 4: 5/5 in all 
groups. 
Mice were challenged with 10-7 cells 31-52PRO tumor cells 
s.q. on day 0 and tumor size was measured weekly by 
calculating tumor area. Tumor size for each group is 
expressed as mean tumor area of 5 mice. Statistical 
differences between experimental and control groups was 









B mfib 14-12 
C PBS ++ 
D mfib 14-12 ++ 
0 2 4 6 8 10 12 
CS Response (units) 
ng ure 4. --Treatment with Mfib 14-12 Blocks the Suppression of the fidoptiue 
Transfer of Contact Sensitiuity to PCI. CS responses to PCI in mice receiuing 
lOug SF mfib 14-12 (i.p.) 24 hours prior to transfer of anti-l-J -treated 
immune SC (Croup D) were significantly different (p < 0.001) from mice 
which receiued no immune cells (Groups fl and B) or no mfib (Group C). 
Treatment with antibody alone (Group B) had no effect when compared to 
control animals (Group A). 
fill animals were challenged with PCI immediately after some groups (C and 
D) receiued 3 h 107 immune spleen cells. CS responses are reported as the 
difference between the unchallenged left ear and the challenged right ear. 
1 unit = 10-3cm. Error bars indicate S.E.M. Statistical difference was 





Group Primed Transfer 
TNP-SC 
CS Response (units) 
ng ure 5. --Treatment with Mfib 14-12 BlocksTole ranee Induction to TNP and 
Conuerts a Tolerogenic Signal to an Immunogenic Signal. Mice receiuing lOug SF mRb 
14-12 (i.p.) 24hours priorto transferor a tolerogenic signal (TNP-SC i.u.; Group F) 
developed CS responses on subsequent challenge which were significantly different 
(p « 0.001) from mice receiuing no mRb (Groups D and E) or no cell transfer (Groups 
R, B, and C). Treatment with mflb alone (Group C) had no effect when compared to 
control animals (Group R). 
Rll animals were challenged with PCI immediately after some groups (D,E, and F) 
receiued 2 h 107 TNP-SC. CS responses are reported as the difference between the 
unchallenged left earand the challenged right ear. 1 unit * 10-3cm. Error bars 
indicate S.E.M. Statistical difference was established by analysis with the student s 
t test. Each group consisted of 5 animals. 
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enzyme-linked immunosorbent assay 
fetal calf serum 
Hank's balanced salt solution 
Interleukin-2 
killer cells 
Lymphokine-activated killer cells 
monoclonal antibody 
methy1cholanthrene 
mammary tumor virus 
natural killer cells 
polyacrylamide gel electrophoresis 
phosphate-buffered saline 
picryl chloride 
saturated ammonium sulfate 
spleen cells 
serum-free 
specific pathogen free 
sheep red blood cells 
cytotoxic T cells 
contrasuppressor T cells 
delayed-type hypersensitivity effector T cell 
helper T cell 
suppressor T cell 





thymectomy, lethal radiation, bone marrow salvage 
ultraviolet 
Vicia villosa adherent 
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